Review



amd070 called wk1  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress amd070 called wk1
    Growth inhibition and apoptosis of B cell lymphoma cell lines upon treatment with CXCR4 antagonists. ( a ) Structure of the CXCR4 antagonists AMD3100, <t>AMD070,</t> and <t>WK1.</t> ( b ) Cell growth of SuDHL4 (as GCB-DLBCL model), RI-1 and U2932 (as NGCB-DLBCL model), and BL2 (as Burkitt model) cell lines in the presence of increasing concentrations (range: 1–90 µM) of the CXCR4 antagonists AMD3100, AMD070, its niacin derivative WK1 and niacin, respectively, as determined by the EZ4U proliferation assay and expressed by percentage of normal absorption. ( c ) Annexin V positivity of BL2 (as Burkitt model) and SuDHL4 (as GCB-DLBCL model) cells treated with AMD3100, AMD070 and its niacin derivative WK1 (concentration: 40 µM; for 48 h) as determined by flow cytometry and compared to the DMSO treated control cells. The treatments and Annexin V staining were performed in triplicate and the medians ± standard deviations are depicted. ( d ) Percentage of cleaved caspase 3 positive BL2 (as Burkitt model) and SuDHL4 (as GCB-DLBCL model) cells treated with 40 µM of AMD070 or 20 µM and 40 µM of its niacin derivative WK1 for 24 h as determined by flow cytometry and compared to the DMSO treated control cells. The treatments and cleaved caspase staining were performed in triplicate and the medians ± standard deviations are depicted.
    Amd070 Called Wk1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/amd070+called+wk1/Mavorixafor/pmc06801866-193-25-11
    Average 94 stars, based on 6 article reviews
    amd070 called wk1 - by Bioz Stars, 2026-09
    94/100 stars

    Images

    1) Product Images from "The CXCR4–CXCL12 -Axis Is of Prognostic Relevance in DLBCL and Its Antagonists Exert Pro-Apoptotic Effects In Vitro"

    Article Title: The CXCR4–CXCL12 -Axis Is of Prognostic Relevance in DLBCL and Its Antagonists Exert Pro-Apoptotic Effects In Vitro

    Journal: International Journal of Molecular Sciences

    doi: 10.3390/ijms20194740

    Growth inhibition and apoptosis of B cell lymphoma cell lines upon treatment with CXCR4 antagonists. ( a ) Structure of the CXCR4 antagonists AMD3100, AMD070, and WK1. ( b ) Cell growth of SuDHL4 (as GCB-DLBCL model), RI-1 and U2932 (as NGCB-DLBCL model), and BL2 (as Burkitt model) cell lines in the presence of increasing concentrations (range: 1–90 µM) of the CXCR4 antagonists AMD3100, AMD070, its niacin derivative WK1 and niacin, respectively, as determined by the EZ4U proliferation assay and expressed by percentage of normal absorption. ( c ) Annexin V positivity of BL2 (as Burkitt model) and SuDHL4 (as GCB-DLBCL model) cells treated with AMD3100, AMD070 and its niacin derivative WK1 (concentration: 40 µM; for 48 h) as determined by flow cytometry and compared to the DMSO treated control cells. The treatments and Annexin V staining were performed in triplicate and the medians ± standard deviations are depicted. ( d ) Percentage of cleaved caspase 3 positive BL2 (as Burkitt model) and SuDHL4 (as GCB-DLBCL model) cells treated with 40 µM of AMD070 or 20 µM and 40 µM of its niacin derivative WK1 for 24 h as determined by flow cytometry and compared to the DMSO treated control cells. The treatments and cleaved caspase staining were performed in triplicate and the medians ± standard deviations are depicted.
    Figure Legend Snippet: Growth inhibition and apoptosis of B cell lymphoma cell lines upon treatment with CXCR4 antagonists. ( a ) Structure of the CXCR4 antagonists AMD3100, AMD070, and WK1. ( b ) Cell growth of SuDHL4 (as GCB-DLBCL model), RI-1 and U2932 (as NGCB-DLBCL model), and BL2 (as Burkitt model) cell lines in the presence of increasing concentrations (range: 1–90 µM) of the CXCR4 antagonists AMD3100, AMD070, its niacin derivative WK1 and niacin, respectively, as determined by the EZ4U proliferation assay and expressed by percentage of normal absorption. ( c ) Annexin V positivity of BL2 (as Burkitt model) and SuDHL4 (as GCB-DLBCL model) cells treated with AMD3100, AMD070 and its niacin derivative WK1 (concentration: 40 µM; for 48 h) as determined by flow cytometry and compared to the DMSO treated control cells. The treatments and Annexin V staining were performed in triplicate and the medians ± standard deviations are depicted. ( d ) Percentage of cleaved caspase 3 positive BL2 (as Burkitt model) and SuDHL4 (as GCB-DLBCL model) cells treated with 40 µM of AMD070 or 20 µM and 40 µM of its niacin derivative WK1 for 24 h as determined by flow cytometry and compared to the DMSO treated control cells. The treatments and cleaved caspase staining were performed in triplicate and the medians ± standard deviations are depicted.

    Techniques Used: Inhibition, Proliferation Assay, Concentration Assay, Flow Cytometry, Control, Staining

    Related Articles

    Generated:

    Article Title: The CXCR4–CXCL12 -Axis Is of Prognostic Relevance in DLBCL and Its Antagonists Exert Pro-Apoptotic Effects In Vitro
    Article Snippet: The identity of the DLBCL cell lines was confirmed by variable number tandem repeats (VNTR) analysis using Power Plex 16 System (Promega, Madison, WI, USA), and verified at the online service of the DSMZ cell bank [ ]. .. All cell lines were treated with the commercially available CXCR4 antagonists (MedChemExpress, Sollentuna, Sweden) AMD3100 and AMD070 [ ], and the novel niacin derivative of AMD070 called WK1, which was generated by us, in a range from 1 μM to 90 μM. ..



    Similar Products

    amd070 called wk1  (MedChemExpress)
    94
    MedChemExpress amd070 called wk1
    Growth inhibition and apoptosis of B cell lymphoma cell lines upon treatment with CXCR4 antagonists. ( a ) Structure of the CXCR4 antagonists AMD3100, <t>AMD070,</t> and <t>WK1.</t> ( b ) Cell growth of SuDHL4 (as GCB-DLBCL model), RI-1 and U2932 (as NGCB-DLBCL model), and BL2 (as Burkitt model) cell lines in the presence of increasing concentrations (range: 1–90 µM) of the CXCR4 antagonists AMD3100, AMD070, its niacin derivative WK1 and niacin, respectively, as determined by the EZ4U proliferation assay and expressed by percentage of normal absorption. ( c ) Annexin V positivity of BL2 (as Burkitt model) and SuDHL4 (as GCB-DLBCL model) cells treated with AMD3100, AMD070 and its niacin derivative WK1 (concentration: 40 µM; for 48 h) as determined by flow cytometry and compared to the DMSO treated control cells. The treatments and Annexin V staining were performed in triplicate and the medians ± standard deviations are depicted. ( d ) Percentage of cleaved caspase 3 positive BL2 (as Burkitt model) and SuDHL4 (as GCB-DLBCL model) cells treated with 40 µM of AMD070 or 20 µM and 40 µM of its niacin derivative WK1 for 24 h as determined by flow cytometry and compared to the DMSO treated control cells. The treatments and cleaved caspase staining were performed in triplicate and the medians ± standard deviations are depicted.
    Amd070 Called Wk1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/amd070+called+wk1/Mavorixafor/pmc06801866-193-25-11
    Average 94 stars, based on 1 article reviews
    amd070 called wk1 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Growth inhibition and apoptosis of B cell lymphoma cell lines upon treatment with CXCR4 antagonists. ( a ) Structure of the CXCR4 antagonists AMD3100, AMD070, and WK1. ( b ) Cell growth of SuDHL4 (as GCB-DLBCL model), RI-1 and U2932 (as NGCB-DLBCL model), and BL2 (as Burkitt model) cell lines in the presence of increasing concentrations (range: 1–90 µM) of the CXCR4 antagonists AMD3100, AMD070, its niacin derivative WK1 and niacin, respectively, as determined by the EZ4U proliferation assay and expressed by percentage of normal absorption. ( c ) Annexin V positivity of BL2 (as Burkitt model) and SuDHL4 (as GCB-DLBCL model) cells treated with AMD3100, AMD070 and its niacin derivative WK1 (concentration: 40 µM; for 48 h) as determined by flow cytometry and compared to the DMSO treated control cells. The treatments and Annexin V staining were performed in triplicate and the medians ± standard deviations are depicted. ( d ) Percentage of cleaved caspase 3 positive BL2 (as Burkitt model) and SuDHL4 (as GCB-DLBCL model) cells treated with 40 µM of AMD070 or 20 µM and 40 µM of its niacin derivative WK1 for 24 h as determined by flow cytometry and compared to the DMSO treated control cells. The treatments and cleaved caspase staining were performed in triplicate and the medians ± standard deviations are depicted.

    Journal: International Journal of Molecular Sciences

    Article Title: The CXCR4–CXCL12 -Axis Is of Prognostic Relevance in DLBCL and Its Antagonists Exert Pro-Apoptotic Effects In Vitro

    doi: 10.3390/ijms20194740

    Figure Lengend Snippet: Growth inhibition and apoptosis of B cell lymphoma cell lines upon treatment with CXCR4 antagonists. ( a ) Structure of the CXCR4 antagonists AMD3100, AMD070, and WK1. ( b ) Cell growth of SuDHL4 (as GCB-DLBCL model), RI-1 and U2932 (as NGCB-DLBCL model), and BL2 (as Burkitt model) cell lines in the presence of increasing concentrations (range: 1–90 µM) of the CXCR4 antagonists AMD3100, AMD070, its niacin derivative WK1 and niacin, respectively, as determined by the EZ4U proliferation assay and expressed by percentage of normal absorption. ( c ) Annexin V positivity of BL2 (as Burkitt model) and SuDHL4 (as GCB-DLBCL model) cells treated with AMD3100, AMD070 and its niacin derivative WK1 (concentration: 40 µM; for 48 h) as determined by flow cytometry and compared to the DMSO treated control cells. The treatments and Annexin V staining were performed in triplicate and the medians ± standard deviations are depicted. ( d ) Percentage of cleaved caspase 3 positive BL2 (as Burkitt model) and SuDHL4 (as GCB-DLBCL model) cells treated with 40 µM of AMD070 or 20 µM and 40 µM of its niacin derivative WK1 for 24 h as determined by flow cytometry and compared to the DMSO treated control cells. The treatments and cleaved caspase staining were performed in triplicate and the medians ± standard deviations are depicted.

    Article Snippet: All cell lines were treated with the commercially available CXCR4 antagonists (MedChemExpress, Sollentuna, Sweden) AMD3100 and AMD070 [ ], and the novel niacin derivative of AMD070 called WK1, which was generated by us, in a range from 1 µM to 90 µM.

    Techniques: Inhibition, Proliferation Assay, Concentration Assay, Flow Cytometry, Control, Staining